Back to Emergency Medicine
Emergency Medicinev2021Evidence-Based

Pulmonary Embolism Syncope-Anemia-Renal Dysfunction (PE-SARD) Score

Estimates risk of early major bleeding in patients with acute pulmonary embolism (PE). This validated risk assessment tool helps clinicians identify PE patients at higher risk for bleeding complications within 30 days of diagnosis, assisting in treatment decisions and management planning.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
pe sard score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Pulmonary Embolism Syncope-Anemia-Renal Dysfunction (PE-SARD) Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within emergency medicine.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

PE-SARD Score = 1.5×(if syncope) + 2.5×(if anemia Hgb <12 g/dL) + 1×(if renal dysfunction GFR <60 mL/min)

Clinical Pearls & Practice Notes

  • Simple 3-variable score for bleeding risk assessment in acute PE
  • Syncope contributes 1.5 points to the total score
  • Anemia (Hgb <12 g/dL) contributes 2.5 points - highest weighted factor
  • Renal dysfunction (GFR <60 mL/min/1.73m²) contributes 1 point
  • Score ranges from 0 to 5 points total
  • Low risk (0 points): 0.6% bleeding incidence at 30 days
  • Intermediate risk (1-2.5 points): 1.5% bleeding incidence at 30 days
  • High risk (>2.5 points): 2.5% bleeding incidence at 30 days
  • Externally validated in multiple large registries (RIETE, COMMAND VTE)
  • Better performance compared to existing bleeding scores in PE setting
  • Assists in shared decision-making for PE management
  • Should be used in conjunction with thrombotic risk assessment
  • Does not replace clinical judgment for individual patient assessment
  • Consider patient-specific factors not captured in the score
  • Useful for identifying patients requiring modified anticoagulation strategies

Evidence & Literature Citations

  1. Barrios D, Rosa-Salazar V, Morillo R, Nieto R, Fernández-Golfín C, Zamorano JL, et al. An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism: The Syncope, Anemia, Renal Dysfunction (PE-SARD) Bleeding Score. Chest. 2021 Sep;160(3):992-1000. doi: 10.1016/j.chest.2021.04.063.
  2. Lobo JL, Zorrilla V, Aizpuru F, Grau E, Jiménez D, Prandoni P, et al. External validation of the PE-SARD risk score for predicting early bleeding in acute pulmonary embolism in the RIETE Registry. Thromb Res. 2024 Mar;235:176-181. doi: 10.1016/j.thromres.2024.01.016.
  3. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. External validation of the Pulmonary Embolism-Syncope, Anemia, and Renal Dysfunction bleeding score for early major bleeding in patients with acute pulmonary embolism: from the COMMAND VTE Registry-2. J Thromb Thrombolysis. 2024 Aug;58(2):357-365. doi: 10.1007/s11239-024-02988-4.

Score Interpretation Ranges

Low Risk0 – 0 pts

Low bleeding risk

Intermediate Risk1 – 2.5 pts

Intermediate bleeding risk

High Risk2.5 – 5 pts

High bleeding risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.